DMU PARABOL, APHP, CHU Bichat-Claude Bernard, Département d'anesthésie Reanimation, 46 Rue Henri Huchard, 75018, Paris, France.
UMR 1149, INSERM, Immunorecepteur Et Immunopathologie Rénale, CHU Bichat-Claude Bernard, 46 Rue Henri Huchard, 75018, Paris, France.
BMC Pulm Med. 2024 Apr 3;24(1):161. doi: 10.1186/s12890-024-02977-z.
Prior studies have assessed the impact of the pretransplantation recipient body mass index (BMI) on patient outcomes after lung transplantation (LT), but they have not specifically addressed early postoperative complications. Moreover, the impact of donor BMI on these complications has not been evaluated. The first aim of this study was to assess complications during hospitalization in the ICU after LT according to donor and recipient pretransplantation BMI.
All the recipients who underwent LT at Bichat Claude Bernard Hospital, Paris, between January 2016 and August 2022 were included in this observational retrospective monocentric study. Postoperative complications were analyzed according to recipient and donor BMIs. Univariate and multivariate analyses were also performed. The 90-day and one-year survival rates were studied. P < 0.05 was considered to indicate statistical significance. The Paris-North Hospitals Institutional Review Board approved the study.
A total of 304 recipients were analyzed. Being underweight was observed in 41 (13%) recipients, a normal weight in 130 (43%) recipients, and being overweight/obese in 133 (44%) recipients. ECMO support during surgery was significantly more common in the overweight/obese group (p = 0.021), as were respiratory complications (primary graft dysfunction (PGD) (p = 0.006), grade 3 PDG (p = 0.018), neuroblocking agent administration (p = 0.008), prone positioning (p = 0.007)), and KDIGO 3 acute kidney injury (p = 0.036). However, pretransplantation overweight/obese status was not an independent risk factor for 90-day mortality. An overweight or obese donor was associated with a decreased PaO2/FiO2 ratio before organ donation (p < 0.001), without affecting morbidity or mortality after LT.
Pretransplantation overweight/obesity in recipients is strongly associated with respiratory and renal complications during hospitalization in the ICU after LT.
先前的研究评估了移植前受体体重指数(BMI)对肺移植(LT)后患者结局的影响,但尚未专门探讨术后早期并发症。此外,尚未评估供体 BMI 对这些并发症的影响。本研究的首要目标是根据供体和受体移植前 BMI 评估 LT 后 ICU 住院期间的并发症。
本观察性回顾性单中心研究纳入了 2016 年 1 月至 2022 年 8 月期间在巴黎比沙医院接受 LT 的所有受者。根据受者和供体 BMI 分析术后并发症。还进行了单变量和多变量分析。研究了 90 天和 1 年的生存率。p<0.05 表示具有统计学意义。巴黎北部医院机构审查委员会批准了该研究。
共分析了 304 名受者。41 名(13%)受者体重不足,130 名(43%)受者体重正常,133 名(44%)受者超重/肥胖。超重/肥胖组术中 ECMO 支持显著更常见(p=0.021),呼吸并发症(原发性移植物功能障碍(PGD)(p=0.006)、3 级 PGD(p=0.018)、神经阻滞剂使用(p=0.008)、俯卧位(p=0.007))和 KDIGO 3 级急性肾损伤(p=0.036)也更常见。然而,移植前超重/肥胖状态不是 90 天死亡率的独立危险因素。超重或肥胖供体与器官捐献前 PaO2/FiO2 比值降低相关(p<0.001),但不影响 LT 后的发病率或死亡率。
移植前受者超重/肥胖与 LT 后 ICU 住院期间的呼吸和肾脏并发症密切相关。